Remove Protein Production Remove Science Remove Small Molecule
article thumbnail

Target-directed cancer: protein-ligand interactions  

Drug Target Review

The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials. We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production.

article thumbnail

A Look Back

Dark Matter Blog

My last stop at Arrakis Therapeutics is with a company targeting RNA with small molecules. I was enticed by Arrakis’ founder Jen Petter to serve in one more operational role, leading the research group at Arrakis as the company launched as one of the first biotechs to target RNA with drug-like small molecules.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Global advances in synthetic biology

Drug Discovery World

The company is developing a pan-European biotech studio network covering areas where synthetic biology can create disruptive solutions and high market value products. A study published in Science 3 outlines how the compound, named cilagicin, works well in mice and employs a novel mechanism to attack MRSA, C. References .

article thumbnail

The future outlook for mRNA therapies

Drug Discovery World

“This recognition has led to the development of programs encompassing vaccines, RNAi, and small molecules that span diverse therapeutic areas. It’s worth noting that the approach of small molecules interacting with mRNA biology represents a relatively new and potentially broader and more effective strategy.

Therapies 130
article thumbnail

What to expect from PEGS Europe 2023: Day 3

Drug Discovery World

Thereafter, the following presentations will take place: Melody Shahsavarian, PhD, Digital Biologics Platform, Large Molecules Research, Sanofi, on: ‘Enhancing antibody discovery with generative AI’. Hiroki Shirai, PhD, Coordinator, RIKEN Center for Computational Science, on: ‘Applying deep learning anomaly detection to antibody structures’.

article thumbnail

Codon Digest: Bacteria Resist Every Virus

Codon

. 🧪 Papers AI + Bio Protein-specific signal peptides for mammalian vector engineering. Evolutionary-scale prediction of atomic-level protein structure with a language model. DeepBindGCN: Integrating molecular vector representation with graph convolutional neural networks for accurate protein-ligand interaction prediction.

Virus 52
article thumbnail

Codon Digest: Discovering Antibiotics with Deep Learning

Codon

Read Programming inactive RNA-binding small molecules into bioactive degraders. Science Advances. Read Maximizing protein production by keeping cells at optimal secretory stress levels using real-time control approaches. Science Advances. Science Advances. Molecular Therapy. Nature Communications.

DNA 52